Katja Zimmermann

USPTO Granted Patents = 43 (Patent Applications = 17)

CIPO Patents = 3 (Patent Applications = 12)

EPO Patents = 33 (Patent Applications = 43)

Average Co-Inventor Count = 8.4

ph-index = 8

Forward Citations = 167(Granted Patents)

Company Filing History:

22 out of 378

Bayer Pharma Aktiengesellschaft

patents

19 out of 721

Bayer Intellectual Property Gmbh

patents

6 out of 443

The Broad Institute, Inc.

The General Hospital Corporation

patents

6. 5 out of 12,160

Bayer Aktiengesellschaft

patents

7. 1 out of 1

Bayer Pharma Aktiengellschaft

patent

8. 1 out of 5

Bayer Aktiengellschaft

patents

9. 1 out of 1

Bayer Pharma Aktiegellschaft

patent

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Triazolones

mIDH1 Inhibitors

Benzimidazoles

Uracils

Dicyanopyridines

Piperidines

Indazole Derivatives

Dihydropyridine Derivatives

Chymase Inhibitors

Prodrugs

Cyanopyridines

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486248 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2025-12-02),

2. 11787797 - 4,5-annulated 1,2,4-triazolones (2023-10-17),

3. 11713304 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2023-08-01),

4. 11130745 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2021-09-28),

5. 10968216 - 4,5-annulated 1,2,4-triazolones (2021-04-06),

6. 10919862 - Fused imidazoles as mIDH1 inhibitors (2021-02-16),

7. 10815215 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2020-10-27),

8. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

9. 10414734 - 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors (2019-09-17),

10. 10370339 - N-Methylbenzimidazoles as mIDH1 inhibitors (2019-08-06),

11. 10300062 - Bicyclically substituted uracils and the use thereof (2019-05-28),

12. 10179123 - 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors (2019-01-15),

13. 10138226 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-11-27),

14. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors (2018-11-27),

15. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

Title: The Innovative Mind of Inventor Katja Zimmermann

Introduction: Inventor Katja Zimmermann, a visionary hailing from Düsseldorf, Germany, is a pioneering force in the world of inventions and patents. Despite the common misconception, Katja Zimmermann is a male inventor who has made significant contributions to various industries through his groundbreaking innovations.

Latest Patents: Katja Zimmermann's latest patents showcase his ingenuity and forward-thinking approach to problem-solving. His recent inventions have revolutionized sectors such as technology, healthcare, and sustainability, earning him recognition as a leading inventor in the global landscape.

Career Highlights: Throughout his illustrious career, Katja Zimmermann has accumulated a remarkable portfolio of patents that have reshaped industries and improved the lives of many. His dedication to innovation and relentless pursuit of excellence have set him apart as a trailblazer in the field of inventions.

Collaborations: Katja Zimmermann has collaborated with top-tier companies, research institutions, and universities to bring his inventions to life. His ability to work seamlessly with diverse teams and experts has led to the successful development and commercialization of cutting-edge technologies.

Conclusion: In conclusion, Katja Zimmermann's innovative spirit and passion for creating impactful solutions have solidified his reputation as a prolific inventor. His contributions to the world of patents and inventions continue to inspire future generations to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.